Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03072134 · ClinicalTrials.gov registry record · Phase 1
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03072134 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 12 participants.
The verdict
NCT03072134, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches. Based on the encouraging results of our preclinical studies which demonstrate improved efficacy without added toxicity, the paradigm of delivering a novel oncolytic adenovirus via a neural stem cell line in combination with radiation and chemotherapy is well-suited for evaluation in newly diagnosed malignant gliomas. The standard-of-care allows application of virotherapy as neoadjuvant therapy and assessment of the cooperative effects with radiation/chemotherapy without altering the standard treatment.
Interventions
- BIOLOGICAL Neural stem cells loaded with an oncolytic adenovirus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03072134
The ClinicalTrials.gov registry entry for NCT03072134 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neural stem cells loaded with an oncolytic adenovirus is the first listed.
NCT03072134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03072134 about?
NCT03072134 is a clinical study titled "Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma". Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches. Based on the encouraging results of our preclinical studies which demonstrate improved efficacy without added toxicity, the paradigm ...
What is the current status of trial NCT03072134?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-04-24. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT03072134?
The interventions under investigation include: Neural stem cells loaded with an oncolytic adenovirus (BIOLOGICAL).
Who is sponsoring clinical trial NCT03072134?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.